Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Mallinckrodt
AstraZeneca
Baxter
Express Scripts

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

TREXIMET Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Treximet patents expire, and what generic alternatives are available?

Treximet is a drug marketed by Currax and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has sixteen patent family members in fourteen countries.

The generic ingredient in TREXIMET is naproxen sodium; sumatriptan succinate. There are forty-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the naproxen sodium; sumatriptan succinate profile page.

Drug patent expirations by year for TREXIMET
Drug Prices for TREXIMET

See drug prices for TREXIMET

Recent Clinical Trials for TREXIMET

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dent Neurologic InstituteN/A
GlaxoSmithKlinePhase 2/Phase 3
Premiere Research InstitutePhase 2/Phase 3

See all TREXIMET clinical trials

Recent Litigation for TREXIMET

Identify potential future generic entrants

District Court Litigation
Case NameDate
NAUTILUS NEUROSCIENCES, INC. v. EDICT PHARMACEUTICALS PVT. LTD.2011-07-20
Pozen Inc. v. Sun Pharma Global FZE2011-05-26
Pozen Inc. v. Teva Pharmaceuticals USA Inc.2009-04-24

See all TREXIMET litigation

PTAB Litigation
PetitionerDate
Graybar Pharmaceuticals, LLC2015-11-12

See all TREXIMET litigation

Synonyms for TREXIMET
811794-26-0
Naproxen / sumatriptan
Naproxen mixture with sumatriptan
Naproxen sodium mixture with sumatriptan succinate
Sumatriptan mixture with naproxen
Sumatriptan succinate and naproxen sodium
Sumatriptan succinate mixture with naproxen sodium
Trexima

US Patents and Regulatory Information for TREXIMET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Currax TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Currax TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TREXIMET

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Currax TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008   Start Trial   Start Trial
Currax TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015   Start Trial   Start Trial
Currax TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-002 May 14, 2015   Start Trial   Start Trial
Currax TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008   Start Trial   Start Trial
Currax TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TREXIMET
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 500 mg/85 mg ➤ Subscribe   Start Trial

Supplementary Protection Certificates for TREXIMET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411900 1190013-1 Sweden   Start Trial PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
1411900 C300481 Netherlands   Start Trial PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
0984957 PA2011005,C0984957 Lithuania   Start Trial PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
1411900 C01411900/01 Switzerland   Start Trial PRODUCT NAME: ESOMEPRAZOL + NAPROXEN; REGISTRATION NO/DATE: SWISSMEDIC 61330 06.05.2011
0984957 SPC/GB11/013 United Kingdom   Start Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Baxter
Medtronic
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.